Androgen receptor inhibitors in treating prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Androgens and the androgen receptor (AR) are critical drivers of prostate cancer.
• Current FDA-approved AR inhibitors target the AR ligand-binding domain (LBD).
• Treatment resistance leading to castration-resistant prostate cancer (CRPC) is a major clinical challenge.

Purpose of the Study:

• To review existing FDA-approved AR antagonists for prostate cancer.
• To summarize emerging AR-targeting agents and strategies.
• To highlight novel approaches for overcoming treatment resistance.

Main Methods:

• Literature review of FDA-approved drugs and ongoing research.
• Analysis of mechanisms driving AR reactivation in CRPC.
• Summary of novel AR inhibitors and AR degradation agents.

Main Results:

• Current AR inhibitors targeting the LBD show initial efficacy but resistance emerges.
• AR reactivation in CRPC occurs via gene amplification, mutation, and splice variants.
• Novel therapeutic strategies include targeting different AR domains and AR protein degradation.

Conclusions:

• Effective inhibition of reactivated AR signaling is necessary for CRPC treatment.
• New AR-targeting agents and degradation strategies offer promise for overcoming resistance.
• Continued research into novel AR-targeted therapies is vital for improving patient outcomes.